Orbactiv

Active Ingredient(s): Oritavancin Diphosphate
FDA Approved: * August 6, 2014
Pharm Company: * MEDICINES CO
Category: Antibiotics

* This drug may consist of multiple approval dates, manufacturers, or distributors. If applicable, they would be listed below under "NDC Database Records".



Orbactiv Overview

Oritavancin (INN, also known as LY333328, Orbactiv) is a novel semisynthetic glycopeptide antibiotic for the treatment of serious Gram-positive bacterial infections. Its chemical structure as a lipoglycopeptide is similar to vancomycin.[1] In August 2014, the United States FDA approved oritavancin for treatment of skin infections.[2] Contents 1 In vitro activity 1.1 Mechanism 2 Clinical trials 3 History 4 References 5 External links In vitro activ...

Read more Orbactiv Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source: en.wikipedia.org/wiki/Oritavancin

Recent Orbactiv Forums:

Be the first to start a discussion about this drug.

Possible Dosages for this and Related Drugs:

Oritavancin Diphosphate
  • Powder: 400mg/vial
  • Powder, For Injection Solution, Lyophilized Powder: 1200 Mg.
Note: Above list includes dosages for all drugs with the same combination of active ingredients.

NDC Database Records for Orbactiv: (2 results)

Sorted by National Drug Code
  • 65293-015 Orbactiv 400 mg Intravenous Injection, Powder, Lyophilized, for Solution by The Medicines Company
  • 70842-140 Orbactiv 400 mg Intravenous Injection, Powder, Lyophilized, for Solution by Melinta Therapeutics, Inc.

Other drugs which contain Oritavancin Diphosphate or a similar ingredient: (1 result)






Note: All times displayed are GMT - 7.

This information has been independently compiled and is for informational purposes only. It is not intended to be a substitute for medical advice from a qualified healthcare professional; nor is it intended to diagnose, treat, cure or prevent any disease. For more details please see the Medical Disclaimer. This page was last updated on 21 January 2019.

We are committed to your privacy.

Copyright © 2005-2019 All Rights Reserved. MedsChat® is a registered trademark of Limelight Innovations L.L.C. 9888 W Belleview Ave #5000, Denver, CO, 80123, USA